Company news
Longeveron Inc. news in 2025
Longeveron Inc.'s news releases, calls and decks from 2025, newest first.
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
December 29, 2025
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy
December 17, 2025
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
December 3, 2025
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
December 2, 2025
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
December 1, 2025
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
November 19, 2025
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy
November 12, 2025
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
November 4, 2025
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
October 28, 2025
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
October 27, 2025
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
October 6, 2025
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
October 1, 2025
Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
September 22, 2025
Longeveron® Announces Key Leadership Updates
September 3, 2025
Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference
August 20, 2025
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update
August 13, 2025
Longeveron Announces Closing Of Up To $17.5 Million Public Offering
August 11, 2025
Longeveron Announces Up To $17.5 Million Public Offering
August 8, 2025
Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025
August 5, 2025
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
July 21, 2025
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
July 8, 2025
Longeveron® Appoints Than Powell as Chief Business Officer
June 26, 2025
Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)
June 24, 2025
Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
June 9, 2025
Longeveron® to Attend BIO International Convention 2025
May 20, 2025
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
May 12, 2025
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
May 8, 2025
Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
May 2, 2025
Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025
April 22, 2025
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease
March 20, 2025
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease
March 11, 2025
Longeveron® to Present at the 37th Annual Roth Conference
March 5, 2025
Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update
February 28, 2025
Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025
February 21, 2025
Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™
February 18, 2025